MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ARCT had -$16,107K decrease in cash & cash equivalents over the period. -$17,332K in free cash flow.

Cash Flow Overview

Change in Cash
-$16,107K
Free Cash flow
-$17,332K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Revenue
17,152 -
Total research and development
87,736 -
General and administrative
10,398 -
Other
-3,063 -
Net loss
-13,448 -23,256
Depreciation and amortization
763 1,580
Share-based compensation expense
5,729 12,862
Foreign currency transaction loss
-170 -149
Accounts receivable
-9,253 13,230
Prepaid expense and other assets
57 -4,145
Right-of-use assets
-955 -1,880
Accounts payable
-5,045 3,429
Accrued liabilities
-5,417 -14,301
Deferred revenue
-8,986 -12,086
Lease liabilities
-1,068 -2,065
Net cash used in operating activities
-17,151 -40,893
Acquisition of property and equipment
181 137
Net cash used in investing activities
-181 -137
Proceeds from exercise of stock options
640 469
Proceeds from the issuance of common stock under equity plans
585 -
Proceeds from debt
0 15,000
Payments on debt obligations
0 15,000
Net cash provided by financing activities
1,225 469
Net decrease in cash, cash equivalents and restricted cash
-16,107 -40,561
Cash and cash equivalents at beginning of period
293,913 -
Cash and cash equivalents at end of period
237,245 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. (ARCT)